论文部分内容阅读
近日,加拿大素麻简医药公司宣布说有关SAV001-H(一种对抗艾滋病毒的疫苗)的第一阶段临床试验已经取得成功。从2012年3月到上个月为止,试验进行了一年多,实验设计用于检验该药物用于活人体上的“安全性、耐受性以及免疫效应”.第一阶段试验中研究人员开始观察药物是否会在动物身上起作用,以确保其不会对人体产生奇怪、有害的影响,因此风险极高。SAV001-H实验结果非常完美:在对艾滋病感染者进行随机、病患不知情、安慰剂控制的条件下,以及无症状人群的实验中,都
Recently, Canadian Medicine Company of Canada announced that it has succeeded in the first phase of its trial on SAV001-H, a vaccine against HIV. From March 2012 until the last month, the trial was conducted over a year and was designed to test the “safety, tolerability and immune effects” of the drug on live humans. "In the first phase of the trial Researchers are starting to see if drugs can work on animals to make sure they do not have strange, detrimental effects on the body and are therefore at very high risk. The results of the SAV001-H experiment are perfect: in a randomized, blinded, placebo-controlled trial of people living with HIV and in asymptomatic populations